Hemoperfusion in COVID-19

Area of Science:

• Critical Care Medicine
• Immunology
• Infectious Diseases

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection triggers a hyperinflammatory response, or cytokine storm.
• This cytokine storm can lead to sepsis-like conditions, capillary leakage, thrombosis, and multi-organ damage.
• Existing research on hemoperfusion for SARS-CoV-2 is limited and shows inconsistencies.

Purpose of the Study:

• To review the effectiveness and risks of hemoperfusion techniques in severe SARS-CoV-2 infection.
• To identify the potential role of hemoperfusion in managing hyperinflammation and its complications.
• To highlight the need for further research to establish consensus on hemoperfusion use.

Main Methods:

• Review of case series and randomized controlled trials on hemoperfusion cartridges (HA330, CytoSorb, Polymyxin, oXiris, Seraph 100).
• Analysis of reported outcomes related to clinical benefits and adverse events.
• Synthesis of existing evidence to identify gaps and inconsistencies.

Main Results:

• Various hemoperfusion cartridges have been explored for severe SARS-CoV-2.
• Inconsistent findings exist across studies regarding efficacy and safety.
• No established consensus on the use of hemoperfusion in SARS-CoV-2 patients.

Conclusions:

• Hemoperfusion shows potential in managing SARS-CoV-2-induced hyperinflammation.
• Further high-quality research is essential to validate clinical benefits.
• Identifying optimal patient populations and timing for hemoperfusion is crucial.